ReviewDrug design, development and therapy2026
DIF: Concepts, Measurement, and Impact in Patient-Focused Drug Development and Regulatory Decision-Making.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differential Item Functioning (DIF) is critical for Patient-Focused Drug Development (PFDD), particularly in validating Patient-Reported Outcome (PRO) tools. This study links DIF analysis to regulatory decision-making. DIF directly impacts the reliability of drug approval evidence, trial result interpretation, and subgroup consistency evaluation. However, it is not a primary driver of regulatory approval decisions, which prioritize substantial evidence of efficacy and safety. As a "regulatory-impacting measurement bias", DIF detection ensures measurement fairness (a prerequisite for valid cross-group comparisons) and supports the pursuit of validity by identifying tool flaws for optimization, reveals group-specific response differences, and safeguards the accuracy/comparability of PRO data, thereby supporting precise drug development and reliable efficacy assessments. Methodologically, DIF analysis relies on Classical Test Theory (CTT), Item Response Theory (IRT), and methods such as Mantel-Haenszel, logistic regression, and hybrid approaches, but faces caveats including strict sample size requirements (eg, large calibration samples for IRT models) and challenges in detecting multidimensional DIF. With the growing application of PROs in clinical trials, DIF detection has become an indispensable step to mitigate biases that could mislead drug development decisions. This article systematically reviews DIF's definition, classification, detection methods, application in drug development, and existing challenges. Integrating the latest global research and regulatory evidence, it discusses DIF's practical implications for clinical trial design (eg, subgroup analysis, cross-cultural trial adaptation) and regulatory decision-making in PFDD. The work aims to provide theoretical reference and practical guidance for relevant research and practice, highlighting the need to address methodological limitations to strengthen DIF's role in PFDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.